60 DEGREES PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $2.20M
- P/E (TTM)
- –
- Dividend yield
- –
About 60 Degrees Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes therapies to prevent and treat infectious conditions. Its primary commercial product is Arakoda, an approved tafenoquine regimen used for malaria prevention. The company also maintains development programs targeting fungal, viral, and vector-borne diseases. Its clinical pipeline explores additional regimens containing tafenoquine, alongside compounds such as celgosivir and botanical extracts derived from Australian chestnut trees. It provides treatments for individuals exposed to infectious illnesses and distributes therapies through commercial pharmaceutical distributors.
The company maintains its corporate headquarters in Washington, D.C. Beyond its primary operations in the United States, it manages an international presence through a majority-owned subsidiary located in Sydney, Australia. This subsidiary, 60P Australia Pty Ltd, oversees sub-licensing rights for products across multiple territories outside the United States.
Summary of the business section of 60 Degrees Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- 60 DEGREES PHARMACEUTICALS, INC.
- Founded
- 2022
- Headquarters
- Washington, DC
- Address
- 1025 Connecticut Avenue Nw, Suite 1000 20036
- Phone
- (202) 327-5422
- Employees
- 3, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RBSM LLP, Las Vegas, Nevada
Stock & identifiers
- Ticker
- SXTP
- Other tickers
- SXTPW
- Exchange
- Nasdaq
- IPO date
- Jul 13, 2023
- Shares outstanding
- 4M, Aug 14, 2026
- Public float
- $3.34M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-4 reverse, Mar 30, 2026; 1-for-4 reverse, Jan 20, 2026; 1-for-5 reverse, Mar 27, 2025; 1-for-5 reverse, Feb 24, 2025; 1-for-12 reverse, Aug 14, 2024; 1-for-12 reverse, Aug 12, 2024
- SEC CIK
- 1946563
- CUSIP
- 83006G500
- ISIN
- US83006G5009
- EIN
- 45-2406880
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Geoffrey S. Dow | President and CEO, Director | 35,250 |
| Kristen Landon | Chief Operating Officer | 4,540 |
| Tyrone Miller | CFO | 26,370 |
| Eric Francois | Director | – |
| Cheryl Xu | Director | 13,816 |
Employees
Headcount reported in annual reports
“As of December 31, 2025 , we had a total of three employees, all of whom are full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 23, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 28, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 15, 2023 | Late filing | Notification of late filing |
| Nov 3, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 13, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 14, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |